Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1418-1426

  Frustaci, S ^a   Buonadonna, A ^a   Galligioni, E ^a   Favaro, D ^a   De Paoli, A ^a   Lo Re, G ^a   Sorio, R ^a   Tumolo, S ^a   Monfardini, S ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EPIRUBICIN; IFOSFAMIDE; MESNA; ONDANSETRON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; RINGER SOLUTION;

ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONY FORMING UNIT GM; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEIOMYOSARCOMA; LEUKOPENIA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN INFLAMMATION; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

EID: 0030957418     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1418     Document Type: Article

References (29)

1. Verwey J, Pinedo HM: Soft tissue sarcomas, in Slevin ML, Staquet MJ (eds): Randomized Trials in Cancer: A Critical Review by Sites. New York, NY, Raven, 1986, pp 569-581
2. Elias AD: Chemotherapy for soft-tissue sarcomas. Clin Orthop 289:94-105, 1993
3. Mazanet R, Antman KH: Sarcomas of soft tissue and bone. Cancer 68:463-473, 1991
4. Elias AD: The clinical management of soft tissue sarcomas. Semin Oncol 19:19-25, 1992
5. Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 19:670-686, 1992
6. Chevallier B, Montcuquet P, Fachini T, et al: Phase II study of epirubicin in advanced soft tissue sarcoma. Bull Cancer 77:991-995, 1990
7. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/ phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:1477-1483, 1987
8. Bonfante V, Bonadonna G, Villani F, et al: Preliminary phase I study of 4′-epiadriamycin. Cancer Treat Rep 63:915-918, 1979
9. 2) epirubicin. Cancer Chemother Pharmacol 24:61-64, 1989
10. Feld R, Wierzbicki R, Walde PLD, et al: Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol 10:297-303, 1992
11. Tjuljandin SA, Doig RG, Sobol MM, et al: Pharmacokinetics and toxicity of two schedules of high-dose epirubicin. Cancer Res 50:5095-5101, 1990
12. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 80:556-566, 1988
13. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
14. Antman KH, Elias A: Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 17:7-15, 1990 (suppl 2)
15. Gottlieb JA, Benjamin RS, Baker LH, et al: Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60:199-203, 1976
16. Buesa JM, Mouridsen HT, van Oosterom AT, et al: High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2:307-309, 1991
17. Gottlieb JA, Baker LH, O'Bryan RB, et al: Adriamycin (NSC 123127) used alone and in combination for soft tissue and bone sarcomas. Cancer Chemother Rep 6:271-282, 1975
18. Lucas P, Spielmann M: Traitement médical des sarcomes des tissus mous de l'adulte. Bull Cancer 72:183-201, 1985
19. Frustaci S, Lo Re G, Crivellari D, et al: Retrospective analysis of the CYVADIC regimen in advanced soft tissue sarcomas. Tumori 75:152-155, 1989
20. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
21. Elias A, Ryan L, Sulkes A, et al: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208-1216, 1989
22. Sieward WP, Verweij J, Somers R, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15-21, 1993
23. Toma S, Palumbo R, Canavese G, et al: Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/ or metastatic sarcomas. Cancer Chemother Pharmacol 31:222-227, 1993 (suppl 2)
24. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
25. Frustaci S, Foladore S, Buonadonna A, et al: Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 4:669-672, 1993
26. O'Bryan RM, Baker LH, Gottlieb JE, et al: Dose-response evaluation of Adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
27. Antman K, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126-131, 1989
28. Benjamin RS, Legha SS, Patel SR, et al: Single-agent ifosfamide studies in sarcomas of the soft tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol 31:174-179, 1993 (suppl 2)
29. Le Cesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995